HighTower Advisors’s Anavex Life Sciences AVXL Stock Holding History

HighTower Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,000	Closed	-$2K	–	3300
2021 Q3	$2K	Buy	+2,000	New	+$39.8K	﹤0.01%	3095

Other funds holding AVXL

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

HighTower Advisors's AVXL Position: Q1 2022 in Review

HighTower Advisors sold out of Anavex Life Sciences (AVXL) in Q1 2022, closing a stake of 10,278 shares — an estimated $178K sold.

HighTower Advisors first reported a position in AVXL in Q4 2020 and held it in 5 quarters. The position peaked at $190K in Q2 2021. 139 funds tracked by Wall St. Rank hold AVXL as of Q1 2022.

HighTower Advisors reported no remaining Anavex Life Sciences position as of Q1 2022 after selling out during the quarter.
HighTower Advisors sold 10,278 Anavex Life Sciences shares in Q1 2022, an estimated $178K.
HighTower Advisors first reported a position in Anavex Life Sciences in Q4 2020 and held it in 5 quarters.
HighTower Advisors's Anavex Life Sciences position peaked at $190K in Q2 2021.
139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2022.

Based on HighTower Advisors's 13F filing for Q1 2022, filed 12 May 2022.